|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
EP2298807A3
(de)
*
|
2004-07-30 |
2011-05-18 |
Rinat Neuroscience Corp. |
Gegen das Amyloid-beta-Peptid gerichtete Antikörper und Verfahren zu deren Anwendung
|
|
SG165322A1
(en)
|
2005-08-31 |
2010-10-28 |
Schering Corp |
Engineered anti-il-23 antibodies
|
|
DE602006009834D1
(de)
|
2005-09-01 |
2009-11-26 |
Schering Corp |
Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
|
|
PL2289909T3
(pl)
|
2005-11-30 |
2015-04-30 |
Abbvie Inc |
Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
|
|
SG2014013437A
(en)
|
2005-11-30 |
2014-07-30 |
Abbott Lab |
Monoclonal antibodies and uses thereof
|
|
AU2007275467B2
(en)
|
2006-07-14 |
2013-12-05 |
Ac Immune S.A. |
Humanized antibody against amyloid beta
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
AU2007334499B2
(en)
|
2006-12-14 |
2014-04-24 |
Merck Sharp & Dohme Corp. |
Engineered anti-TSLP antibody
|
|
LT2436696T
(lt)
|
2007-01-05 |
2017-08-25 |
University Of Zurich |
Anti-beta-amiloido antikūnas ir jo panaudojimas
|
|
IL199534A
(en)
|
2007-01-05 |
2013-01-31 |
Univ Zuerich |
An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
|
|
WO2008103473A1
(en)
|
2007-02-23 |
2008-08-28 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
|
SI2426144T1
(sl)
|
2007-02-23 |
2019-02-28 |
Merck Sharp & Dohme Corp. |
Umetno proizvedena anti-IL23P19 antitelesa
|
|
EP2486928A1
(de)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Verfahren zur Behandlung von Amyloidosen
|
|
NZ579297A
(en)
|
2007-02-28 |
2012-03-30 |
Schering Corp |
Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
|
|
CA2679381A1
(en)
|
2007-02-28 |
2008-09-04 |
Schering Corporation |
Engineered anti-il-23r antibodies
|
|
EP2117540A1
(de)
|
2007-03-01 |
2009-11-18 |
Probiodrug AG |
Neue verwendung von glutaminyl-cyclase-hemmern
|
|
JP5667440B2
(ja)
|
2007-04-18 |
2015-02-12 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
|
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
|
AU2008311367B2
(en)
|
2007-10-05 |
2014-11-13 |
Ac Immune S.A. |
Use of anti-amyloid beta antibody in ocular diseases
|
|
CN102257131A
(zh)
|
2008-12-19 |
2011-11-23 |
先灵公司 |
用于哺乳动物细胞培养的给料添加剂及使用方法
|
|
AU2009328505B2
(en)
|
2008-12-19 |
2014-11-27 |
Panima Pharmaceuticals Ag |
Human anti-alpha-synuclein autoantibodies
|
|
PL2403528T3
(pl)
|
2009-03-02 |
2017-08-31 |
Aduro Biotech Holdings, Europe B.V. |
Przeciwciała przeciwko ligandowi indukującemu proliferację (APRIL)
|
|
US20120128673A1
(en)
|
2009-05-20 |
2012-05-24 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
|
EP2459594A1
(de)
|
2009-07-31 |
2012-06-06 |
N.V. Organon |
Vollständig menschliche antikörper gegen btla
|
|
EP3023438B1
(de)
|
2009-09-03 |
2020-03-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr-antikörper
|
|
WO2011029920A1
(en)
|
2009-09-11 |
2011-03-17 |
Probiodrug Ag |
Heterocylcic derivatives as inhibitors of glutaminyl cyclase
|
|
KR101898739B1
(ko)
|
2009-11-04 |
2018-09-13 |
머크 샤프 앤드 돔 코포레이션 |
조작된 항－ｔｓｌｐ 항체
|
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
|
US9181233B2
(en)
|
2010-03-03 |
2015-11-10 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
|
EA022420B1
(ru)
|
2010-03-10 |
2015-12-30 |
Пробиодруг Аг |
Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
|
|
EP2558494B1
(de)
|
2010-04-15 |
2018-05-23 |
AbbVie Inc. |
Amyloid-beta-bindende proteine
|
|
EP2560953B1
(de)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Hemmer der glutaminylzyklase
|
|
WO2012004367A1
(en)
|
2010-07-09 |
2012-01-12 |
N.V. Organon |
Agonistic antibody to cd27
|
|
EP2598882B1
(de)
|
2010-07-30 |
2017-07-26 |
AC Immune S.A. |
Sichere und funktionelle humanisierte antikörper für die verwendung in der behandlung von einer amyloidose
|
|
WO2012024187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
|
US8530670B2
(en)
|
2011-03-16 |
2013-09-10 |
Probiodrug Ag |
Inhibitors
|
|
TR201810298T4
(tr)
|
2011-03-31 |
2018-08-27 |
Merck Sharp & Dohme |
İnsan programlı ölüm reseptörü PD-1'e karşı antikorların stabil formülasyonları ve ilgili tedaviler.
|
|
PT2723379T
(pt)
|
2011-06-23 |
2018-11-14 |
Univ Of Zuerich |
Moléculas de ligação anti-alfa-sinucleína
|
|
MX2016000750A
(es)
|
2013-08-02 |
2016-08-05 |
Aduro Biotech Holdings Europe B V |
Combinacion de agonistas de cd27 e inhibicion del punto de control inmunologico para estimulacion del sistema inmunologico.
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
AU2014317009A1
(en)
|
2013-09-05 |
2016-03-10 |
Aduro Biotech Holdings, Europe B.V. |
CD70-binding peptides and method, process and use relating thereto
|
|
NL2011406C2
(en)
|
2013-09-06 |
2015-03-10 |
Bionovion Holding B V |
Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
|
|
MX2016007578A
(es)
|
2013-12-16 |
2016-10-03 |
Genentech Inc |
Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
|
|
MY198017A
(en)
|
2014-08-19 |
2023-07-26 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
|
JP7000322B2
(ja)
|
2015-12-16 |
2022-02-04 |
メルク・シャープ・アンド・ドーム・コーポレーション |
抗ｌａｇ３抗体および抗原結合性フラグメント
|
|
US11230591B2
(en)
|
2016-04-20 |
2022-01-25 |
Merck Sharp & Dohme Corp. |
CMV neutralizing antigen binding proteins
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
|
TWI796329B
(zh)
|
2017-04-07 |
2023-03-21 |
美商默沙東有限責任公司 |
抗－ilt4抗體及抗原結合片段
|
|
EP3609922A2
(de)
|
2017-04-13 |
2020-02-19 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp-alpha-antikörper
|
|
BR112019022873A8
(pt)
|
2017-05-02 |
2023-04-11 |
Merck Sharp & Dohme |
Formulação, e, vaso ou dispositivo de injeção.
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
CN111201037B
(zh)
|
2017-08-22 |
2024-04-02 |
比奥根Ma公司 |
含有抗β淀粉样蛋白抗体的药物组合物
|
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
|
EP3694552A1
(de)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap-antikörper und verwendungen davon
|
|
CN109970857B
(zh)
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
|
WO2019148410A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1 antibodies
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
|
TWI851600B
(zh)
|
2018-09-13 |
2024-08-11 |
美國德州系統大學評議委員會 |
新穎lilrb4抗體及其用途
|
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
|
MX2021004928A
(es)
|
2018-10-31 |
2021-06-08 |
Merck Sharp & Dohme Llc |
Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos.
|
|
AU2020404984A1
(en)
|
2019-12-17 |
2022-07-14 |
Chinook Therapeutics, Inc. |
Methods of treating IgA nephropathy with atrasentan
|
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
|
JP2023524464A
(ja)
|
2020-04-30 |
2023-06-12 |
サイロパ ビー．ブイ． |
抗ｃｄ１０３抗体
|
|
PE20230840A1
(es)
|
2020-06-25 |
2023-05-19 |
Merck Sharp And Dohme Llc |
Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
|
|
IL301533A
(en)
|
2020-09-24 |
2023-05-01 |
Merck Sharp ַ& Dohme Llc |
Stable compositions of programmed death receptor 1 (PD-1) antibodies and hyaluronidase variants and parts thereof and methods of using them
|
|
EP4284834A1
(de)
|
2021-01-29 |
2023-12-06 |
Merck Sharp & Dohme LLC |
Zusammensetzungen von antikörpern des rezeptors 1 für programmierten tod und verfahren zur herstellung der zusammensetzungen daraus
|
|
WO2024092240A1
(en)
|
2022-10-28 |
2024-05-02 |
Chinook Therapeutics, Inc. |
Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody
|
|
WO2024206738A1
(en)
|
2023-03-31 |
2024-10-03 |
Immunai Inc. |
Humanized anti-trem2 antibodies
|